 <h1>Jakafi Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>ruxolitinib</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about ruxolitinib. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Jakafi.</p><h2>In Summary</h2><p><b>Common side effects of Jakafi include:</b> anemia, balance impairment, dizziness, headache, labyrinthitis, meniere's disease, neutropenia, thrombocytopenia, vertigo, and orthostatic dizziness. <b>Other side effects include:</b> weight gain, and flatulence.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to ruxolitinib: oral tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, ruxolitinib (the active ingredient contained in Jakafi) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking ruxolitinib:</p><p>
<i>More common</i>
</p><ul>
<li>Black, tarry stools</li>
<li>bladder pain</li>
<li>bleeding gums</li>
<li>blood in the urine or stools</li>
<li>blurred vision</li>
<li>bruising</li>
<li>chills</li>
<li>cloudy urine</li>
<li>collection of blood under the skin</li>
<li>cough</li>
<li>coughing up blood</li>
<li>deep, dark purple bruise</li>
<li>difficult, burning, or painful urination</li>
<li>difficulty in breathing or swallowing</li>
<li>dizziness</li>
<li>fever</li>
<li>frequent urge to urinate</li>
<li>headache</li>
<li>hoarseness</li>
<li>increased menstrual flow or vaginal bleeding</li>
<li>itching, pain, redness, or swelling</li>
<li>large, flat, blue or purplish patches in the skin</li>
<li>lower back or side pain</li>
<li>nervousness</li>
<li>nosebleeds</li>
<li>painful or difficult urination</li>
<li>pale skin</li>
<li>paralysis</li>
<li>pinpoint red spots on the skin</li>
<li>pounding in the ears</li>
<li>prolonged bleeding from cuts</li>
<li>pus in the urine</li>
<li>red or dark brown urine</li>
<li>small, red or purple spots on the skin</li>
<li>slow or fast heartbeat</li>
<li>sore throat</li>
<li>swelling</li>
<li>tenderness, pain, swelling, warmth, skin discoloration, and prominent superficial veins over the affected area</li>
<li>tightness in the chest</li>
<li>troubled breathing with exertion</li>
<li>ulcers, sores, or white spots in the mouth</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Painful blisters on the trunk of the body</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of ruxolitinib may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Bloated or full feeling</li>
<li>diarrhea</li>
<li>excess air or gas in the stomach or bowels</li>
<li>feeling of constant movement of self or surroundings</li>
<li>passing gas</li>
<li>sensation of spinning</li>
<li>skin rash</li>
<li>weight gain</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to ruxolitinib: oral tablet</i></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Bruising (up to 23.2%)</p>
<p><b>Common</b> (1% to 10%): Herpes zoster<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Flatulence, gastrointestinal bleeding<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Urinary tract infection (up to 14.4%)<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Anemia (up to 96.1%), thrombocytopenia (up to 69.8%), neutropenia (up to 18.7%)<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Tuberculosis </p>
<p><b>Frequency not reported</b>: Progressive multifocal leukoencephalopathy<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hypercholesterolemia (up to 17.4%), weight gain (up to 10%)<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Dizziness (up to 18.1%), headache (up to 14.8%)</p>
<p><b>Common</b> (1% to 10%): Intracranial bleeding<sup>[Ref]</sup></p><h3>General</h3><p>The most common adverse reactions were anemia, thrombocytopenia, bruising, dizziness, and headache.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Bleeding (up to 32.6%)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): ALT increased (up to 27.1%), AST increased (up to 19.3%)<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Jakafi (ruxolitinib)." Incyte Corporation, Wilmington, DE. </p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p></div>
<div class="more-resources" id="moreResources">
<h2>More about Jakafi (ruxolitinib)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>14 Reviews</li>
<li>Drug class: multikinase inhibitors</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Jakafi &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Myelofibrosis</li>
<li>Myeloproliferative Disorders</li>
<li>Graft-versus-host disease</li>
<li>Polycythemia Vera</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to ruxolitinib: oral tablet</i></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Bruising (up to 23.2%)</p><p><b>Common</b> (1% to 10%): Herpes zoster<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Flatulence, gastrointestinal bleeding<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Urinary tract infection (up to 14.4%)<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Anemia (up to 96.1%), thrombocytopenia (up to 69.8%), neutropenia (up to 18.7%)<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Tuberculosis </p><p><b>Frequency not reported</b>: Progressive multifocal leukoencephalopathy<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hypercholesterolemia (up to 17.4%), weight gain (up to 10%)<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Dizziness (up to 18.1%), headache (up to 14.8%)</p><p><b>Common</b> (1% to 10%): Intracranial bleeding<sup>[Ref]</sup></p><h3>General</h3><p>The most common adverse reactions were anemia, thrombocytopenia, bruising, dizziness, and headache.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Bleeding (up to 32.6%)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): ALT increased (up to 27.1%), AST increased (up to 19.3%)<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Jakafi (ruxolitinib)." Incyte Corporation, Wilmington, DE. </p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><h2>More about Jakafi (ruxolitinib)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>14 Reviews</li>
<li>Drug class: multikinase inhibitors</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Jakafi &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Myelofibrosis</li>
<li>Myeloproliferative Disorders</li>
<li>Graft-versus-host disease</li>
<li>Polycythemia Vera</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>